A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.
Also called NCT01755156
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 402 participants
- Sponsor
- Registry
-
NCT01755156 -
2012-003670-11
-
- Other papers using this trial's data
- A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01755156. Randomized; triple masking; primary purpose treatment. Start 2013-01-11 (actual); primary completion 2016-03-16 (actual). Results posted on 2017-03-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Matching placebo to omarigliptin
- Intervention (Drug)
- Glimepiride
- Intervention (Drug)
- Matching placebo to glimepiride
- Intervention (Drug)
- Insulin glargine
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01755156- Content hash
03b76d8c400283375ccd419724fa034de7b2b9760025562dce1e2ab9cbde7d2d